Weise Amy M - Barbara Ann Karmanos Cancer Institute, Wayne State University

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 84 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

XMT-1660: A Phase I, First-in-human Trial of a B7-H4-directed Dolasynthen Antibody-Drug Conjugate in Ovarian, Endometrial, and Breast Cancers

Robert Burger,Erika Hamilton,Sylvia Adams,Hyo Han,Alexander Spira,Antonio Giordano,Arvind Chaudhry,Ritesh Parajuli,Judy Wang,Amy Weise,Nour Abuhadra, Patrick McNamara,Kevin Kalinsky

Gynecologic Oncology (2024)

引用0浏览0引用

Interim Analysis of ABM-1310, a Blood-Brain Barrier-Penetrant BRAF Inhibitor, in Patients with BRAF V600-mutated Solid Tumors

Sarina A. Piha-Paul,Macarena Ines De La Fuente,Fabio Iwamoto,Seema Nagpal,Amy M. Weise,Jay-Jiguang Zhu,Sunandana Chandra, Chen, Yali Fu, Zandong Yang,Katy K. Tsai

Journal of Clinical Oncologyno. 16_suppl (2024): 3107-3107

引用0浏览0引用

Supplementary Figures 1-2 from Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity

Jennifer B. Jacob,Elena Quaglino,Olga Radkevich-Brown,Richard F. Jones,Marie P. Piechocki,Joyce D. Reyes,Amy Weise,Augusto Amici,Wei-Zen Wei

openalex（2023）

引用0浏览0引用

Supplementary Fig 3 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination with Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer

Aditya Bardia, Shanu Modi,Mafalda Oliveira,Javier Cortés, Mario Campone,Brigette B.Y., Luc Dirix,Amy Weise,Becker Hewes,Iván Díaz-Padilla,Yu Han,Priya Deshpande,Tanay S. Samant,Karen Rodriguez Lorenc, He Wang,Fei Su,Mariana Chávez‐MacGregor

openalex（2023）

引用0浏览0引用

A Phase 1, Multicenter, Open-Label Study of a New BRAF Inhibitor ABM-1310 in Adult Patients (pts) with BRAFv600-mutated Solid Tumors

Sarina A. Piha-Paul,Seema Nagpal,Amy M. Weise,Fadi S. Braiteh, Chen, Charles Qing Huang, William Liu, Yong Hu,Zane Yang,Katy K. Tsai

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination with Cemiplimab in Advanced Melanoma: Expansion Cohort Analysis

Omid Hamid,Amy Weise,Karl D. Lewis,Tae Min Kim,Meredith McKean,Nehal J. Lakhani,John Kaczmar,Kyriakos P. Papadopoulos,Shuquan Chen,Jayakumar Mani,Giuseppe Gullo

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2023）

引用0浏览0引用

A Phase 1 Study of Fianlimab (Anti-Lag-3) in Combination with Cemiplimab (Anti-Pd-1) in Patients with Advanced Melanoma: Poor-prognosis Subgroup Analysis

Inderjit Mehmi,Karl D. Lewis,Amy M. Weise,Meredith McKean,Kyriakos P. Papadopoulos,John Crown,Sajeve Samuel Thomas,Eugenia Girda,John M. Kaczmar,Kevin B. Kim,Nehal J. Lakhani,Melinda Lynne Yushak,Omid Hamid,Jayakumar Mani, Fang,Israel Lowy,Giuseppe Gullo

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients with Advanced Liposarcoma, Solid Tumors, or Lymphomas

Mrinal M. Gounder,Todd M. Bauer,Gary K. Schwartz,Amy M. Weise,Patricia LoRusso,Prasanna Kumar,Ben Tao,Ying Hong,Parul Patel,Yasong Lu,Arnaud Lesegretain,Vijaya G. Tirunagaru,Feng Xu,Robert C. Doebele,David S. Hong

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用14浏览0WOS引用

Supplementary Fig 4 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination with Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer

openalex（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn